Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity RatioInventory AverageInvested Capital

China SXT Pharmaceuticals (SXTC) Equity Average (2018 - 2025)

Historic Equity Average for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Q1 2021 value amounting to $17.2 million.

  • China SXT Pharmaceuticals' Equity Average rose 6569.82% to $17.2 million in Q1 2021 from the same period last year, while for Mar 2021 it was $17.2 million, marking a year-over-year increase of 6569.82%. This contributed to the annual value of $14.7 million for FY2025, which is 261.5% up from last year.
  • As of Q1 2021, China SXT Pharmaceuticals' Equity Average stood at $17.2 million, which was up 6569.82% from $14.0 million recorded in Q3 2020.
  • Over the past 5 years, China SXT Pharmaceuticals' Equity Average peaked at $17.2 million during Q1 2021, and registered a low of $10.4 million during Q1 2020.
  • For the 3-year period, China SXT Pharmaceuticals' Equity Average averaged around $13.2 million, with its median value being $12.6 million (2019).
  • In the last 5 years, China SXT Pharmaceuticals' Equity Average soared by 2400.72% in 2020 and then surged by 6569.82% in 2021.
  • Over the past 3 years, China SXT Pharmaceuticals' Equity Average (Quarter) stood at $11.3 million in 2019, then grew by 24.01% to $14.0 million in 2020, then rose by 23.49% to $17.2 million in 2021.
  • Its last three reported values are $17.2 million in Q1 2021, $14.0 million for Q3 2020, and $10.4 million during Q1 2020.